SV40 T/t-common polypeptide inhibits angiogenesis and growth of HER2-overexpressing human ovarian cancer

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Cancer Gene Therapy

• Publication date

  2011-08-26

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/cgt.2011.55PMID 21869825
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Inhibition of metastasis, angiogenesis, and tumor growth by Chinese herbal cocktail Tien-Hsien Liquid

  2010cited by this paper
• Beyond chemotherapy: targeted therapies in ovarian cancer

  2009cited by this paper
• Antiangiogenic drugs in ovarian cancer

  2009cited by this paper
• Epstein-Barr virus nuclear antigen 2 disrupts mitotic checkpoint and causes chromosomal instability.

  2009cited by this paper
• Promising molecular targets in ovarian cancer

  2009cited by this paper
• Antiangiogenic drugs in ovarian cancer

  2008cited by this paper
• Macrophage inhibitory cytokine-1 activates AKT and ERK-1/2 via the transactivation of ErbB2 in human breast and gastric cancer cells.

  2008cited by this paper
• Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition.

  2007cited by this paper
• ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells.

  2006cited by this paper
• Regulation of tumor angiogenesis by thrombospondin-1.

  2006cited by this paper
• Prognostic, predictive and therapeutic implications of HER2 in invasive epithelial ovarian cancer.

  2006cited by this paper
• Increased expression of urokinase-type plasminogen activator mRNA determines adverse prognosis in ErbB2-positive primary breast cancer.

  2006cited by this paper
• HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy

  2006cited by this paper
• Identification of MAPK Phosphorylation Sites and Their Role in the Localization and Activity of Hypoxia-inducible Factor-1α*

  2006cited by this paper
• SV40 T/t-common polypeptide specifically induces apoptosis in human cancer cells that overexpress HER2/neu.

  2006cited by this paper
• A hypoxia-independent hypoxia-inducible factor-1 activation pathway induced by phosphatidylinositol-3 kinase/Akt in HER2 overexpressing cells.

  2005cited by this paper
• Inhibition of Breast and Ovarian Tumor Growth through Multiple Signaling Pathways by Using Retrovirus-mediated Small Interfering RNA against Her-2/neu Gene Expression*

  2004cited by this paper
• Signal transduction and oncogenesis by ErbB/HER receptors.

  2004cited by this paper
• Translational control by MAPK signaling in long-term synaptic plasticity and memory.

  2004cited by this paper
• ErbB receptors: directing key signaling networks throughout life.

  2004cited by this paper
• S6K1−/−/S6K2−/− Mice Exhibit Perinatal Lethality and Rapamycin-Sensitive 5′-Terminal Oligopyrimidine mRNA Translation and Reveal a Mitogen-Activated Protein Kinase-Dependent S6 Kinase Pathway

  2004cited by this paper
• Squalamine and cisplatin block angiogenesis and growth of human ovarian cancer cells with or without HER-2 gene overexpression

  2002cited by this paper
• Tumour biology: Herceptin acts as an anti-angiogenic cocktail

  2002cited by this paper
• Role of angiogenesis in tumor growth and metastasis.

  2002cited by this paper
• Differential regulation of tumor angiogenesis by distinct ErbB homo- and heterodimers.

  2002cited by this paper
• Molecular crosstalk between p70S6k and MAPK cell signaling pathways.

  2002cited by this paper
• Identification of Two Sp1 Phosphorylation Sites for p42/p44 Mitogen-activated Protein Kinases

  2002cited by this paper
• HER2 (neu) Signaling Increases the Rate of Hypoxia-Inducible Factor 1α (HIF-1α) Synthesis: Novel Mechanism for HIF-1-Mediated Vascular Endothelial Growth Factor Expression

  2001cited by this paper
• Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis

  2000cited by this paper
• Suppression of tumor growth through disruption of hypoxia-inducible transcription

  2000cited by this paper
• Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1

  2000cited by this paper
• The N-terminal common domain of simian virus 40 large T and small t antigens acts as a transformation suppressor of the HER-2/neu oncogene

  2000cited by this paper
• Elevated expression of activated forms of Neu/ErbB‐2 and ErbB‐3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer

  1999cited by this paper
• Controlled Dimerization of ErbB Receptors Provides Evidence for Differential Signaling by Homo- and Heterodimers

  1999cited by this paper
• ErbB-2 Amplification Inhibits Down-regulation and Induces Constitutive Activation of Both ErbB-2 and Epidermal Growth Factor Receptors*

  1999cited by this paper
• p42/p44 Mitogen-activated Protein Kinases Phosphorylate Hypoxia-inducible Factor 1α (HIF-1α) and Enhance the Transcriptional Activity of HIF-1*

  1999cited by this paper
• Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities.

  1997cited by this paper
• Angiogenesis: a Dynamic Balance of Stimulators and Inhibitors

  1997cited by this paper
• CD36 Mediates the In Vitro Inhibitory Effects of Thrombospondin-1 on Endothelial Cells

  1997cited by this paper
• Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma.

  1997cited by this paper
• Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions.

  1996cited by this paper
• Analysis of the tumor vasculature and metastatic behavior of xenografts of human melanoma cell lines transfected with vascular permeability factor.

  1996cited by this paper
• The biology of erbB-2/neu/HER-2 and its role in cancer.

  1994cited by this paper
• Transrepression of RNA polymerase II promoters by the simian virus 40 small t antigen

  1994cited by this paper
• c-erbB-2/neu overexpression enhances metastatic potential of human lung cancer cells by induction of metastasis-associated properties.

  1994cited by this paper
• Correlation of intrinsic chemoresistance of non-small-cell lung cancer cell lines with HER-2/neu gene expression but not with ras gene mutations.

  1993cited by this paper
• Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer.

  1990cited by this paper
• Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

  1989cited by this paper

• Cellular Protein HAX1 Interacts with the Influenza A Virus PA Polymerase Subunit and Impedes Its Nuclear Translocation

  2012cites this paper
• SV40 T/t-common polypeptide enhances the sensitivity of HER2-overexpressing human cancer cells to anticancer drugs cisplatin and doxorubicin.

  2012cites this paper